AstraZeneca ends late-stage kidney disease trial early after strong data
Share:
(Reuters) - AstraZeneca Plc said on Monday it is concluding its late-stage trial for a form of kidney disease early after the drug being tested showed better-than-expected results. The company said its decision to close the trial early follows a positive recommendation from an independent data monitoring committee.